These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 6130839

  • 1. Alpha methylparatyrosine and tetrabenazine in movement disorders.
    Lang AE, Marsden CD.
    Clin Neuropharmacol; 1982 Dec; 5(4):375-87. PubMed ID: 6130839
    [Abstract] [Full Text] [Related]

  • 2. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
    Jankovic J, Orman J.
    Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tetrabenazine treatment in movement disorders.
    Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S.
    Clin Neuropharmacol; 2004 Mar; 27(5):230-3. PubMed ID: 15602104
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
    Fahn S.
    Adv Neurol; 1983 Mar; 37():267-76. PubMed ID: 6858776
    [Abstract] [Full Text] [Related]

  • 7. Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders.
    Sahin T, Yilmaz R, Akbostanci MC.
    Parkinsonism Relat Disord; 2020 May; 74():36-37. PubMed ID: 32311641
    [No Abstract] [Full Text] [Related]

  • 8. Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia.
    Ankenman R, Salvatore MF.
    J Neuropsychiatry Clin Neurosci; 2007 May; 19(1):65-9. PubMed ID: 17308229
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C, Hunter C, Davidson A, Jankovic J.
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C, Jankovic J.
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [Abstract] [Full Text] [Related]

  • 14. Tetrabenazine for involuntary movement disorders.
    Kingston D.
    Med J Aust; 1979 Jun 30; 1(13):628-30. PubMed ID: 158700
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Therapeutic use of tetrabenazine].
    López Del Val LJ, López-García E, Martínez-Martínez L, Santos-Lasaosa S.
    Rev Neurol; 1979 Jun 30; 48(10):523-33. PubMed ID: 19434587
    [Abstract] [Full Text] [Related]

  • 20. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J, Clarence-Smith K.
    Expert Rev Neurother; 2011 Nov 30; 11(11):1509-23. PubMed ID: 22014129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.